# Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)

> **NCT06391450** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Hannover Medical School** · enrollment: 44 (estimated)

## Conditions studied

- Autosomal Dominant Polycystic Kidney

## Interventions

- **DRUG:** Empagliflozin 10 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06391450
- **Lead sponsor:** Hannover Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-14
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2025-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06391450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06391450, "Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06391450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*